Relay Therapeutics

Relay Therapeutics

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1b
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: RLY-1971 (partner: Genentech)
  • Product link:
  • Funding: $350M stock Oct 2021; $460M IPO Jul 2020; $400M Dec 2018; $63M Dec 2017; $57M A Sep 2016
  • Investors: Softbank

job board

Short description:

Motion-based Drug Design

Drug notes:

RLY-4008 Clin1 multiple cancers; RLY-2608 Clin1 multiple cancers; 3 programs Clin0 oncology, undisclosed

Long description:

Relay Therapeutics is identifying drugs to alter protein kinetics to treat patients with cancer and genetic diseases. Proteins are not stationary - they move, and how they move can inform function and disease. Using their Dynamo platform, Relay is visualizing protein motions in HD movies and pioneering Motion-based Drug Design. The platform combines both deep structural understanding and chemical biology insights with AI and physics-based simulations to harness protein dynamics. With this, Relay can then develop unique hypotheses for how best to modulate a protein’s behavior and identify potential novel allosteric binding sites for therapeutics. Relay’s pipeline includes several promising product candidates in early and preclinical stages.


Relay Therapeutics
Senior / Research Associate, Biology
Cambridge, MA|11 days ago
Relay Therapeutics
Scientist, Biology
Cambridge, MA|14 days ago
Relay Therapeutics
Senior Director, Translational Medicine
Cambridge, MA|18 days ago
Relay Therapeutics
Senior / Principal Scientist, DMPK
Cambridge, MA|18 days ago
Relay Therapeutics
Associate Director, Competitive Intelligence & New...
Cambridge, MA|29 days ago
Relay Therapeutics
Director, Bioinformatics
Cambridge, MA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy